Tavotek Biotherapeutics has raised over $20M in Round A1 and Round A2 financing in the preceding two months. YuanBio Venture Capital led the A1 finance round followed by Oriza Holdings, Ming BioVentures, and New Alliance Capital. Series A2 financing was jointly invested by GF Xinde, CTS Capital, and Lanhu Capital.

Tavotek Biotherapeutics, established in early 2019, received its initial Round A investment from Apricot Capital. Tavotek is committed to using innovation to improve the well-being of patients with unmet medical needs. Presently, the company has two R&D centers: one in Lower Gwynedd, Pennsylvania and another in Suzhou, China.